Development and characterization of parenteral nanoemulsions containing thalidomide

European Journal of Pharmaceutical Sciences

Volumn 42, Issue 3, 2011, Pages 238-245

  Araujo F A ^a   Kelmann, R G ^a   Araujo B V ^a   Finatto, R B ^a   Teixeira, H F ^a   Koester, L S ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Nanoemulsions; Pharmacokinetic simulation; Polymorphism; Reverse dialysis; Spontaneous emulsification; Thalidomide

Indexed keywords

THALIDOMIDE;

ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG FORMULATION; DRUG SOLUBILITY; FOURIER TRANSFORMATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; NANOEMULSION; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; VISCOSITY; X RAY DIFFRACTION; ZETA POTENTIAL;

CRYSTALLOGRAPHY, X-RAY; EMULSIONS; INFUSIONS, PARENTERAL; MICROSCOPY, ELECTRON, TRANSMISSION; NANOTECHNOLOGY; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; THALIDOMIDE; VISCOSITY;

EID: 79251594241     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.11.014     Document Type: Article

References (46)

1. F.H. Allen, and J. Trotter Crystal and molecular structure of thalidomide J. Chem. Soc. D: Chem. Commun. 1970 778 779
2. F.A. Araújo Desenvolvimento de nanoemulsões para administraão intravenosa da talidomida Dissertaão de Mestrado. Programa de Pós-Graduaão em Ciências Farmacêuticas 2010 UFRGS Porto Alegre p. 122
3. S. Benita, and M.Y. Levy Submicron emulsions as colloidal drug carriers for intravenous administration: comprehensive physicochemical characterization J. Pharm. Sci. 82 1993 1069 1079
4. K. Bouchemal, S. Briancon, E. Perrier, and H. Fessi Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation Int. J. Pharm. 280 2004 241 251
5. S.J. Bowcock, A. Minchom, L.R. Yates, and M.M. Ryali Ultra low dose of thalidomide in elderly patients with myeloma Br. J. Haematol. 141 2008 120 122
6. K. Buszello, S. Harnisch, R.H. Muller, and B.W. Muller The influence of alkali fatty acids on the properties and the stability of parenteral O/W emulsions modified with solution HS 15 Eur. J. Pharm. Biopharm. 49 2000 143 149
7. M.R. Caira, S.A. Botha, and D.R. Flanagan Polymorphism of N-(2,6-dioxo-3-piperidyl)pthalimide (thalidomide): structural characterization of a second monoclinic racemic modification J. Chem. Cryst. 24 1 1994 95 99
8. J.P. Carini, C. Pavei, A.P. Silva, G. Machado, A.S. Mexias, V.P. Pereira, S.L. Fialho, and P. Mayorga Solid state evaluation of some thalidomide raw materials Int. J. Pharm. 372 2009 17 23
9. H. Chen, Y. Gu, and Y. Hu Comparison of two polymeric carrier formulations for controlled release of hydrophilic and hydrophobic drugs J. Mater. Sci.: Mater. Med. 19 2008 651 658
10. N. Chidambaram, and D.J. Burgess A novel in vitro release method for submicron sized dispersed systems AAPS Pharm. Sci. 1 1999 E11
11. T. Eriksson, S. Bjorkman, B. Roth, and P. Hoglund Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man J. Pharm. Pharmacol. 52 2000 807 817
12. T. Eriksson, S. Bjorkman, and P. Hoglund Clinical pharmacology of thalidomide Eur. J. Clin. Pharmacol. 57 2001 365 376
13. FDA Inactive Ingredient Database 2010 Food and Drug Administration (FDA) Available at: (September, 2010).
14. A.G. Floyd Top ten considerations in the development of parenteral emulsions Pharm. Sci. Technol. Today 4 1999 134 143
15. M. Giffard, V. Delfosse, G. Sciara, C. Mayer, C. Cambillau, M.E. Hajji, B. Castro, and F. Bonneté Surfactant poloxamer 188 as a new crystallizing agent for urate oxidase Cryst. Growth Des. 9 2009 4199 4206
16. J. Han, S.S. Davis, C. Papandreou, C.D. Melia, and C. Washington Design and evaluation of an emulsion vehicle for paclitaxel. I. Physicochemical properties and plasma stability Pharm. Res. 21 2004 1573 1580
17. ICH-Q2 (R1) Validation of Analytical Procedures, Test and Methodology International Conference on Harmonization, Geneva 2005 Available at: (April, 2009)
18. J.M. Jacobson, J. Spritzler, L. Fox, J.L. Fahey, J.B. Jackson, M. Chernoff, D.A. Wohl, A.W. Wu, T.M. Hooton, B.E. Sha, C.M. Shikuma, L.A. MacPhail, D.M. Simpson, C.B. Trapnell, and N. Basgoz Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease Aids Clinical Trials Group J. Infect. Dis. 180 1999 61 67
19. J.H. Jang, C.K. Kim, H.G. Choi, and J.H. Sung Preparation and evaluation of 2-(allylthio)pyrazine-loaded lipid emulsion with enhanced stability and liver targeting Drug Dev. Ind. Pharm. 35 2009 363 368
20. M. Jumaa, and B.W. Muller The effect of oil components and homogenization conditions on the physicochemical properties and stability of parenteral fat emulsions Int. J. Pharm. 163 1998 81 89
21. M. Jumaa, and B.W. Muller Influence of the non-ionic surfactant PEG-660-12-hydroxy stearate on the surface properties of phospholipid monolayers and their effect on lipid emulsion stability Colloid. Polym. Sci. 277 1999 347 353
22. S. Klang, and S. Benita Design and evaluation of submicron emulsions as colloidal drug carriers for intravenous administration S Benita, Submicron Emulsions in Drug Targeting and Delivery 1998 Harwood Academic Publishers Australia 119 152
23. A. Kogan, I. Popov, V. Uvarov, S. Cohen, A. Aserin, and N. Garti Crystallization of carbamazepine pseudopolymorphs from nonionic microemulsions Langmuir 24 2008 722 733
24. M. Krenn, M.P. Gamcsik, G.B. Vogelsang, O.M. Colvin, and K.W. Leong Improvements in solubility and stability of thalidomide upon complexation with hydroxypropyl-β-cyclodextrin J. Pharm. Sci. 81 1992 685 689
25. F. Lara-Ochoa, G.E. Perez, and F. Mijangos-Santiago Calorimetric determinations and theoretical calculations of polymorphs of thalidomide J. Mol. Struct. 840 2007 97 106
26. ® II, 2010. Intravenous fat emulsion. Available at: http://www.hospira.sk/Files/TPN-Liposyn-II.pdf. (September 2010).
27. F.C. Meldrum, and H. Cölfen Controlling mineral morphologies and structures in biological and synthetic systems Chem. Rev. 108 2008 4332 4432
28. R.H. Müller, S. Schmidt, I. Buttle, A. Akkar, J. Schmitt, and S. Bromer SolEmuls-novel technology for the formulation of i.v. emulsions with poorly soluble drugs Int. J. Pharm. 269 2004 293 302
29. F. Nielloud, G. Marti-Mestres, J.P. Laget, C. Fernandez, and H. Maillols Emulsion formulations: study of the influence of parameters with experimental designs Drug Dev. Ind. Pharm. 22 1996 159 166
30. J.C. Reepmeyer, M.O. Rhodes, D.C. Cox, and J.V. Silverton Characterization and crystal structure of two polymorphic forms of racemic thalidomide J. Chem. Soc., Perkin Trans. 2 1994 2063 2067
31. R.C. Rowe, P.J. Sheskey, and S.C. Owen Pharmaceutical Excipients 2006 Pharmaceutical Press and American Pharmacists Association Electronic version
32. H. Schmidt, B. Rush, G. Simonian, T. Murphy, J. Hsieh, and M. Condon Thalidomide inhibits TNF response and increases survival following endotoxin injection in rats J. Surg. Res. 63 1996 143 146
33. H. Schumacher, R.L. Smith, and R.T. Williams The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution Br. J. Pharm. 25 1965 324 337
34. S. Shi, H. Chen, Y. Cui, and X. Tang Formulation, stability and degradation kinetics of intravenous cinnarizine lipid emulsion Int. J. Pharm. 373 2009 147 155
35. Spectrum Laboratories Inc. Laboratory Product Catalog 2009 Available at: (April 01, 2009).
36. S. Tamilvanan Formulation of multifunctional oil-in-water nanosized emulsions for active and passive targeting of drugs to otherwise inaccessible internal organs of the human body Int. J. Pharm. 381 2009 62 76
37. S. Tamilvanan, and S. Benita The potential of lipid emulsion for ocular delivery of lipophilic drugs Eur. J. Pharm. Biopharm. 58 2004 357 368
38. S.K. Teo, W.A. Colburn, W.G. Tracewell, K.A. Kook, D.I. Stirling, M.S. Jaworsky, M.A. Scheffler, S.D. Thomas, and O.L. Laskin Clinical pharmacokinetics of thalidomide Clin. Pharm. 43 2004 311 327
39. G.B. Vogelsang, and M.A. Higman Chronic graft versus host disease Br. J. Haematol. 125 2004 435 454
40. D.L. Waitzberg, R.S. Torrinhas, and T.M. Jacintho New parenteral lipid emulsions for clinical use J. Parenteral Enteral Nutr. 30 2006 351 367
41. G.J.A. Wanten, and P.C. Calder Immune modulation by parenteral lipid emulsions Am. J. Clin. Nutr. 85 2007 1171 1184
42. J.J. Wang, K.C. Sung, O.Y.P. Hu, C.H. Yeh, and J.Y. Fang Submicron lipid emulsion as a drug delivery system for nalbuphine and its prodrugs J. Controlled Release 115 2006 140 149
43. J. Weiss Mass transport phenomena in oil-in-water emulsions containing surfactant micelles: ostwald ripening Langmuir 16 2000 6833 6838
44. X. Yang, Z. Hu, Y.C. Sui, P.C. Ho, E. Chan, W. Duan, C.G. Boon, and S. Zhou Determination of thalidomide by high performance liquid chromatography: plasma pharmacokinetic studies in the rat J. Pharm. Biomed. Anal. 39 2005 299 304
45. W. Yu, E.S. Tabosa do Egito, G. Barratt, H. Fessi, J.P. Devissaguet, and F. Puisieux A novel approach to the preparation of injectable emulsions by a spontaneous emulsification process Int. J. Pharm. 89 1993 139 146
46. J.B. Zeldis, B.A. Williams, S.D. Thomas, and M.E. Elsayed S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide Clin. Ther. 21 1999 319 330